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In pursuit of efﬁcient pollution control policies
and the health beneﬁts that ﬂow from them, it
can be useful to evaluate the costs and beneﬁts
of speciﬁc actions such as the mandated intro-
duction of a technology like vehicle exhaust
catalysts (VECs). Ex post evaluations allow
realized beneﬁts to be reviewed and the results
to inform future policy decisions. Ex ante eval-
uations can also assist in the selection of
appropriate policy interventions from compet-
ing alternatives. In this study we report on an
evaluation of the short-term health benefits
from the introduction of VECs to gasoline
fueled vehicles in Great Britain. In addition to
providing an evaluation of this particular tech-
nology, this paper illustrates the use of a rela-
tively straightforward, low cost methodology
that could be used more widely to address the
evaluation of other, alternative technologies.
Road transport accounts for significant
proportions of total United Kingdom emis-
sions of oxides of nitrogen (NOx), carbon
monoxide (CO), volatile organic compounds
(VOCs), carbon dioxide (CO2), and particu-
late matter < 10 µg in diameter (PM10), partic-
ularly NOx (52%), VOCs (37%), and CO
(90%) (Quality of Urban Air Review Group
1993). Gasoline-fueled automobiles are the
main source of road transport’s contribution,
accounting for some 50–90% of the sector’s
share of U.K. emissions (Holman 1996), and
in urban areas the contribution from road
transport is even higher. From 1993, to com-
ply with European Commission (EC) Stage I
limits on emissions of CO, VOCs, and NOx,
all new gasoline-engine automobiles in the
United Kingdom have been supplied with
three-way VECs (Salway et al. 1996). A cata-
lyst increases the rate of a chemical reaction
while itself not undergoing any permanent
change (Heck and Farrauto 1995). VECs con-
tain platinum, palladium, and rhodium, which
catalyze the conversion of the incomplete
products of gasoline combustion—NOx,
hydrocarbons, and CO—to N2, H2O, and
CO2. Automobile lead emissions have also
been reduced effectively by the introduction of
VECs because unleaded gasoline is required to
avoid poisoning the catalysts. Surprisingly,
although studies have addressed concerns over
the release of platinum in particular (Helmers
1997; Rosner and Merget 2000; Zereini et al.
1998), there do not seem to have been any
attempts speciﬁcally to assess the health bene-
fits of the reduction in emissions from the
introduction of VECs against their costs, either
in Europe or the United States. This study
appears to represent the first comprehensive
attempt to quantify, in health and economic
terms, the net beneﬁts of this mandated envi-
ronmental technology to Great Britain.
Methods
Using 1992 (the year before catalysts became
compulsory for all new automobiles) as the
base case, we made two evaluations: ﬁrst, an
ex post evaluation of the health effects arising
from the action of VECs on pollutant levels
in urban areas from 1993 to 1998 (the most
recent year for which all the necessary data
were available); second, an ex ante evaluation
of the health beneﬁts projected to 2005, since
full catalyst penetration in the car fleet is
expected by then, assuming a 13-year car life
span (Aguye M. Personal communication).
The evaluation was constrained to short-term
acute health effects in urban areas in the
United Kingdom: These are the effects for
which the most reliable epidemiologic evi-
dence is available (with reference to the
United Kingdom); most of the population
[85%; Office for National Statistics (ONS)
2000] live in urban areas, and this is where
public concern is highest.
Health Risk Assessment Model
To undertake these evaluations, we developed
and applied a health risk assessment model. 
The four principal steps in the modeling
process are illustrated in the ﬂow chart below
(Figure 1), using PM10 data as a worked exam-
ple (for clarity, the example relates only to pri-
mary PM10). In the first step (Figure 1), we
developed a model to estimate reductions in
emissions of NOx, VOCs, CO, and PM10 aris-
ing from the use of VECs. In the second step
we estimated the resulting changes in ambient
urban concentrations for the primary pollutants
CO, VOCs, and primary PM10, and for the
secondary pollutants NO2, O3, and secondary
PM10. In the third step we quantified the
health beneﬁts from these changes in pollution,
in terms of morbidity and mortality, using
exposure–response functions from selected epi-
demiologic studies. Finally, in the fourth step
we used established cost–beneﬁt analysis meth-
ods to carry out a detailed economic valuation
of the selected societal health beneﬁts, which
were then weighed against the costs of VECs.
Estimating reduction in emissions. In the
ﬁrst step (Figure 1), we developed a model to
estimate reductions in urban emissions of NOx,
VOCs, CO, and PM10 arising from the use of
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Research ArticleVECs. The fitting of VECs is estimated to
result in the following reductions in emissions
for gasoline vehicles: CO, 81%; hydrocar-
bons, 89%; NOx, 85%; and PM10, 50%
(Salway et al. 1996). Salway et al. estimated
decreases relative to the previous standard
[United Nations Economic Commission for
Europe (UNECE) regulation 15-04 noncata-
lyst equipped] by applying urban emission
factors (based on experimental measurements
of emissions and distance traveled of vehicles
meeting each standard and driven under
urban test cycle conditions) to urban emis-
sions attributable to gasoline automobiles in
the base year, 1992, then year on year to
1998, and then projected to 2005.
Estimates of national emissions of regulated
pollutants and their source apportionment are
available from the U.K. National Atmospheric
Emissions Inventory (Salway et al. 1996).
Recently a growing number of urban emissions
inventories have also been produced for the
United Kingdom (Hutchinson and Clewley
1996; LRC 1997a, 1997b, 1997c, 1998). On
the basis of these inventories, the contribution
of gasoline automobiles to total urban emis-
sions in 1992 was estimated at 43% for NOx,
87% for VOCs, 8% for primary PM10, and
87% for CO.
Lead emissions from catalyst-equipped
automobiles were assumed to be zero because
of the use of unleaded fuel. Unfortunately, in
the final analysis U.K. data were insufficient
to quantify and value the environmental and
health benefits of reduced lead emissions
solely attributable to catalysts. This represents
an area in which further research is needed.
We estimated increased platinum emissions
arising from the use of vehicle exhaust catalysts
in urban areas from 1993 to 1998 using trafﬁc
data and emissions factors [Artelt et al. 1999;
Simoni S. Personal communication; U.K.
Department of Environment, Transport and
the Regions (DETR) 1999]. This is reported in
the results section.
We estimated the penetration of catalyst-
equipped automobiles into the fleet, year on
year, using data on existing and new car regis-
trations from the DETR (Aguye M. Personal
communication). We allowed for increases in
trafﬁc growth on the basis of the U.K. govern-
ment’s published ﬁgures on trafﬁc growth for
cars and taxis for 1988–1998 and their central
forecast for 1999 to 2005 (DETR 1999);
increases in trafﬁc of 13%, for 1992–1998, and
10% for 1999–2005 were thus derived. In the
absence of emissions projections from sources
other than traffic, the use of these estimates
necessitated the assumption that all other emis-
sions would stay constant over this time. In this
manner, and through the use of relevant emission
factors, we estimated a series of annual urban
emissions from gasoline automobiles from 1992
to 1998 and further projected to 2005.
Estimating changes in concentrations. We
then used these urban emissions reductions
from gasoline automobiles to estimate the
corresponding reductions in ambient urban
concentrations from 1992 to 1998 and those
projected from 1999 to 2005. Estimates of
these changes (step 2) were made for the pri-
mary pollutants VOCs and primary PM10
assuming direct relationships; for the sec-
ondary pollutants NO2 and O3 using relevant
conversion formulae from air pollution mod-
els (Carslaw et al. 1998; Derwent 1999); and
for primary and secondary PM10 together
using a simple source apportionment method
[Airborne Particulate Expert Group (APEG)
1999]. We also estimated the reduction in
carbon monoxide concentrations but
excluded them from the health risk assess-
ment because of current uncertainty over
available exposure–response  functions. 
We estimated reductions in ambient
urban concentrations of regulated pollutants
relative to average urban concentrations in
1992 [National Centre for Environmental
Technology (NETCEN) 1999]. Because we
considered only health end points for short-
term acute effects in urban areas in this evalu-
ation, for primary pollutants it seemed
reasonable to assume direct relationships
between emissions reductions and reductions
in concentrations. Air pollution modeling has
shown that in urban areas, where buildings
prevent dispersion of emissions, low-level
emissions disperse very slowly, so that over
short distances concentrations are directly
proportional to the emission rate of inert pri-
mary pollutants (Williams 1996).
For the secondary pollutants O3 and NO2,
we estimated the effect of reducing precursor
emissions on concentrations using relevant air
pollution models developed by the U.K.
Meteorologic Office and the South East
Institute of Public Health (SEIPH) (Carslaw
et al. 1998; Derwent 1999). We developed a
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Figure 1. Method for evaluation of catalyst pollution abatement (illustrative ﬁgures for primary PM10 to 1998). 
Assess contribution of
gasoline automobiles to
urban emissions in
1992 (8%)
For secondary pollutants, determine the
reduction in total urban precursor
emissions; then relate these to the
reduction in concentration of the
secondary pollutant using the relevant
formula (from air pollution models)
Percentage reduction in total urban
emissions due to catalysts, allowing
for percent of automobiles currently
equipped with catalysts
(2% reduction in 1998)
Apply exposure response function to
derive change in mortality and morbidity
due to reduction in pollutant concentration
(to 1998: 192 deaths brought forward,
235 hospital admissions)
Apply economic valuation to these
changes in health and compare to costs
(Total benefit to1998: £316 million)
Step 1. Reduction in emissions
Step 2. Application of reduction in emissions to concentrations
Step 3. Qualification of health effects
Step 4. Economic evaluation
Apply reduction in emissions to
ambient urban concentrations to
estimate reduction in concentrations
(2% of 7.6 µg/m3 = 0.15 µg/m3 absolute
reduction in primary PM10 concentration in 1998)simple source apportionment method for
PM10 using the latest data available from
APEG (1999). A weighted concentration was
used, based on the contribution of gasoline
car emissions to each fraction of particulate
matter, to take account of the reduction in
both primary emissions and the secondary
precursor emissions. The estimated change in
urban concentrations of these pollutants
attributable to the action of VECs is illustrated
in Figure 2. We also estimated the absolute
reduction in urban concentrations of PM10
(primary and secondary), NO2, and O3 arising
from the reduction in emissions by the use of
VECs in urban areas for each of the years
1993–1998, as well as further projections to
2005.
Quantiﬁcation of health effects. We ana-
lyzed the relationship between human health
impacts and reductions in pollutant concentra-
tions because of the spread of VECs according
to the methods employed by Calthrop
(Maddison et al. 1996). The relationship can be
expressed as
∆Hij = bij × POP ×∆ Ajt,
where ∆Hi = change in health impact i per
year; j = a particular pollutant j emitted from
exhaust pipes; t = transport fuel type—diesel,
gasoline, or unleaded gasoline; bij = slope of
exposure–response function of health effect i
per year with respect to pollutant j; POP =
population exposed to pollutant j; and ∆Ajt =
change in ambient concentration of pollutant
j attributable to emissions of specif ﬁc fuel types.
We quantified the health benefits from
the estimated changes in pollutant concentra-
tions in terms of effects on morbidity and
mortality, using exposure–response functions
from selected epidemiologic studies
[Anderson et al. 1997; Committe on the
Medical Effects of Air Pollution (COMEAP)
1998; Dab et al. 1996; Dockery and Pope
1997; Katsouyanni et al. 1997; Spix et al.
1998; Sunyer et al. 1997; Touloumi et al.
1997], combined with population data for
urban Great Britain in step 3 (ONS 1998,
2000a, 2000b). These epidemiologic studies
were selected from the following reviews and
meta-analyses and are applied to either the
United Kingdom or Europe:
• The European Union Environment
1991–1994 Programme’s Air Pollution and
Health—A European Approach (APHEA)
project, “Short Term Effects of Air Pollution
on Health: A European Approach Using
Epidemiological Time Series Data: The
APHEA Protocol” (Katsouyanni et al. 1996)
• The U.K. Department of Health’s COMEAP
review, Quantification of the Effects of Air
Pollution on Health in the United Kingdom
(COMEAP 1998)
• The Royal Society of Chemistry’s Air
Pollution and Health, a review of current
knowledge in their Issues in Environmental
Science and Technology Series (Hester and
Harrison 1998).
The APHEA project consists of time-series
studies conducted in 15 cities in 11 European
countries, including Greece, Germany,
France, Italy, Poland, The Netherlands, Spain,
Finland, France, Slovakia, and the United
Kingdom. Because of the availability of these
studies, we thought it most appropriate to
assess critically and draw on the existing
studies, rather than to conduct further sepa-
rate meta-analyses. Available individual stud-
ies relevant to the United Kingdom were also
appraised and used to inform selection of
exposure–response functions from the reviews
(Anderson et al. 1996, 1998; Ponce de Leon
et al. 1996; Walters et al. 1995; Wordley
et al. 1997). Available reviews and meta-
analyses from the United States were also
explored where available and used to produce
an upper-bound estimate of health effects
(Dockery and Pope 1997; Pope et al. 1995;
Schwartz 1994).
General criteria set out by Wright et al.
(1997) for selecting epidemiologic studies for
exposure–response assessment were applied
to the selection of studies used in this work;
they were also applied in the APHEA studies,
the World Health Organization study, and
the U.S. studies that have been used as the
main basis for estimating exposure–response
functions in this work (Hutchinson 2001).
These criteria include consistency of ﬁndings
with other studies, quality of exposure data
for the relevant period, statistical precision of
the risk estimates, inclusion of data on expo-
sure–response relationships, and inclusion of
data concerning major confounding factors.
Further discussion of the selection criteria
employed in this study may be found in
Hutchinson (2001).
These epidemiologic studies use time-
series methods for investigating the association
between air pollution levels and ill health in
urban areas. All selected studies controlled for
season and the effect of co-pollutants, and,
where possible, studies conducted in European
cities were used. Thus exposure–response
functions for mortality and hospital admis-
sions for PM10 and O3 and for hospital
admissions only for NO2 were combined with
population, mortality, and hospital admission
data to produce estimates of the numbers of
deaths brought forward and of respiratory
hospital admissions (additional and brought
forward) avoided by the use of VECs in urban
areas. Although exposure–response functions
for NO2 are available for all cause mortality
(Touloumi et al. 1997), there is a lack of con-
sistency among studies, and some studies have
found evidence of confounding with black
smoke (Zmirou et al. 1998) and other vehi-
cle-derived pollutants (Kinney and Özkaynak
1991). In light of this evidence, we judged
that a robust exposure–response function
could not readily be estimated for the effects
of NO2 on mortality.  Therefore we used
only exposure–response functions for hospital
admissions for NO2 in this work.
In line with current practice, we assumed
the health beneﬁts arising from each pollutant
to be additive, and thus estimated total bene-
ﬁts by summing the beneﬁts from the change
in each of the three pollutants considered
here. It is possible that their individual effects
are not simply additive and may, for example,
exacerbate one another. However, in the
absence of estimates of the effects of pollutant
mixes speciﬁc to gasoline-powered vehicles, a
simple additive model was adopted. For car-
cinogenic mixtures, at least, this has been
reported as a reasonable assumption at low
levels (Krewski and Thomas 1992).
For each of the pollutants considered, lin-
earity and the absence of a threshold were
assumed. There has been some debate over the
existence of a threshold for O3, below which
no adverse health effects occur. Although one
study conducted in London for 1987–1992
produced evidence for the existence of a
threshold at 40–60 ppb maximum 8-hr O3
(Ponce de Leon et al. 1996), other studies
have failed to show evidence for such a thresh-
old for effects (COMEAP 1998). Recent work
comparing seasonal ozone concentration has
not contributed further to the identiﬁcation of
a threshold (COMEAP 2002). In this study
we adopted a no-threshold approach and lin-
earity of effects, following the approach of
COMEAP (1998). In light of the debate over
thresholds, our results should be interpreted
with appropriate caution.
The most robust epidemiologic evidence
exists for PM10 and O3, whereas less is 
available for NO2 and CO. After stringent
review, we decided not to estimate the health
effects of CO, VOCs, and lead because 
of uncertainty about the shape of the expo-
sure–response function for CO at the low
concentrations that are found in the United
Kingdom, and lack of exposure–response
Article | Hutchinson and Pearson
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Figure 2. Estimated percent change in urban con-
centration of selected pollutants arising from the
use of vehicle exhaust catalysts, using a model
developed in this work.
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✝functions for the relevant endpoints (mortal-
ity and hospital admissions) for VOCs and
lead. For lead, it was also difﬁcult to identify
clearly the role of catalysts in reducing lead
emissions.
Evaluations of other health end points,
such as symptoms or chronic effects, were not
included because of variations in data quality,
diagnosis patterns, measurement error, diffi-
culties in estimating retrospective exposure,
and consequent uncertainty and lack of agree-
ment over appropriate exposure–response
functions. We selected exposure–response
functions from time-series studies rather than
cohort studies because the available and rele-
vant time-series studies are more robust—in
particular, they are not subject to as many
confounding factors—and there is a greater
availability of such studies conducted for the
United Kingdom and Europe. Most of the
available cohort studies have been conducted
in the United States, thus introducing trans-
ferability issues. Our use of time-series studies
is consistent with the methodology used by
COMEAP (1998). However, also in line with
this approach, similarity of baseline factors
between the United States and United
Kingdom has been assumed here in cases
where short-term U.S.-based studies are used
in central estimates of exposure–response
functions.
To quantify the health effects arising from
changes in air pollution because of the action of
VECs, we applied exposure–response functions
(estimated percentage changes in mortality or
morbidity rates) to the underlying mortality
and morbidity rates for the urban U.K. popula-
tion for 1992. These changes can then be quan-
tiﬁed by applying these percentage increases or
decreases to the urban U.K. population for
1992. This methodology has been widely
reported in the literature [COMEAP 1998;
DETR 1998; Economic Appraisal of the
Health Effects of Air Pollution (EAHEAP)
1999; Maddison et al. 1996].
Thus, data were required on the popula-
tion and on the underlying mortality rate and
the hospital admission rate for Great Britain.
We obtained population statistics for Great
Britain for 1992 (mid-year estimates) from the
ONS, and extracted estimated population ﬁg-
ures for urban areas on the basis of the 1998
ONS area classiﬁcations. This yielded an esti-
mated urban Great Britain population of
47,704,322, which represented 84.6% of the
total Great Britain population (ONS 2000).
The crude annual death rate for Great
Britain for all causes was 1098.19 per 100,000
population in 1992 [1021.91, excluding
deaths from external causes (International
Classiﬁcation of Diseases, 9th ed. [ICD9] codes
> 800); ONS 1998]. Most cities have an
approximately 10% higher mortality rate than
the overall national U.K. rate. However, no
data are available for an overall urban mortal-
ity rate (ONS 1998), so in line with the
COMEAP (1998) report, we assumed the
Great Britain mortality rate to apply to both
urban and rural areas. Consequently, this may
have the effect of biasing the estimates of
health benefits downward. Because data for
monthly mortality were not readily available,
the mortality rate for England and Wales for
summer only (April–September), of 506.8 per
100,000 in 1995, quoted in COMEAP
(1998), was used in the health risk assessment
for O3.
Data on total hospital admissions by diag-
nosis in National Health Service (NHS) hos-
pitals are collected in England by the Hospital
Episodes Statistics (HES; Collin L. Personal
communication) service. Data for all respira-
tory (ICD9 codes 460–519) hospital admis-
sions for 1992–1993 were obtained. By
combining this with the mid-year population
estimate for England in 1992, rates of
1245.83 respiratory hospital admissions per
100,000 population in 1992–1993 and of 770
emergency respiratory hospital admissions per
100,000 population in 1992, were derived. In
line with the approach of the COMEAP
(1998) report, we assumed all hospital admis-
sion rates for England to apply to all urban
Great Britain. Because data by season were not
available, the rate of 345 emergency respira-
tory hospital admissions per 100,000 for
1993, for the summer only (April to
September), quoted in COMEAP, was used in
the O3 health risk assessment.
We obtained the estimated number of
deaths not brought forward and the number of
hospital admissions avoided and not brought
forward, respectively, by making the following
estimates for each year and then summing
them over all the years considered. For exam-
ple, for deaths not brought forward, the esti-
mate was based on the product of the urban
population and the change in the mortality
rate each year (divided by 100,000), where the
change in the mortality rate in each year was
given by the underlying mortality rate in 1992
multiplied by the exposure–response function
for mortality applied to the change in the
concentration in each year produced by the
action of VECs.
Illustration for Primary PM10
• Urban population in 1993 (84.6% of 
Great Britain population of 56,388,087) 
= 47,849,255
• Recorded 1992 urban PM10 concentration 
= 7.57036 µg/m3.
• Estimated 1993 urban PM10 concentration
= 7.57000 µg/m3 (estimated from PM10
emission factors and proportion of urban
PM10 from gasoline fueled automobiles).
• Hence, decrease in concentration because of
VECs = 0.00036 µg/m3.
•M ortality exposure–response coefficient 
= 0.00074.
• Apply to decrease in concentration: 
proportional decrease in mortality 
= 0.00074 × 0.00036 = 0.000015.
• 1992 mortality rate =1098.19.
• Therefore, 1993 decrease in mortality rate 
= 1098.19 × 0.000015 = 0.02
• Number of deaths not brought forward =
(decrease in mortality rate × urban population)
÷ 100,000 = (0.02 × 47,849,255) ÷ 100,000 
= 7.98
We followed the same procedure for hospital
admissions, using changes in the underlying
hospital admission rate as estimated from the
relevant exposure–response functions
selected above.
Economic evaluation. Using established
cost–benefit analysis methods [U.S.
Environmental Protection Agency (EPA)
2000], a detailed economic evaluation of the
selected societal health beneﬁts was conducted,
summed for all pollutants, and then weighed
against the costs of VECs (step 4). Economic
valuations were applied to the estimated
changes in morbidity (respiratory hospital
admissions) and mortality (deaths brought for-
ward). The former are willingness-to-pay
(WTP) estimates that incorporate values for
the pain, suffering, and lost time component
associated with an increase in risk for hospital
admissions—thus they represent the value of
avoiding a stay in hospital. The WTP values
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Table 1. Selected values for mortality, morbidity, and NHS costs to be used for transfer (central estimates).
Health effect Monetary value (£ 1998) Monetary value ($US 1998) Study
VOSLa 1,490,000 2,260,000 EAHEAP 1999
Hospital admission (WTP)b 565.40 856.67 EAHEAP 1999
Hospital admissions for 
respiratory disease (NHS cost)b 2124.10 3218.33 EAHEAP 1999
Cost per catalystc 227.30 344.39 Thornton C. Personal 
communication; 
SMMT 1998
Abbreviations: NHS, National Health Service; SMMT, Society of Motor Manufacturers and Traders.
aAdjusted for age to reﬂect the > 65 age group, which is most likely to be at risk for adverse health effects from air pollu-
tion. bEleven days. cBecause no ofﬁcially published ﬁgures exist for the cost of catalysts in Europe (DETR 1998a), we esti-
mated a weighted average excluding value-added tax retail price for the replacement cost of a catalyst, based on
recommended retail prices for replacement catalysts for the most common makes and models of automobiles purchased
in the United Kingdom (SMMT 1998). These prices are likely to be higher than the actual cost to car manufacturers for the
original catalyst, and therefore will bias the cost component upward. used in this work were selected from an array
of recent contingent valuation methods
(CVM) studies (EAHEAP 1999). Medical
costs were represented by average U.K.
National Health Service hospital admission
costs for respiratory illness (EAHEAP 1999).
Values for changes in mortality due to
changes in pollution were estimated from
recent value of a statistical life (VOSL) studies
(Day 2000; Desvousges et al. 1998; EAHEAP
1999). VOSL represents the cumulative will-
ingness to pay of a population to reduce the
risk of death of a random member of that
population, and is used to represent the value
society places on the enjoyment of a longer,
healthier life (Porter 1999). The central esti-
mate used for VOSL in this study was based
on results derived by EAHEAP (1999). It was
adjusted for age to reﬂect the > 65 age group,
which is most likely to be at risk of suffering
adverse health effects from air pollution. The
EAHEAP report took £2 million (1996
prices) as the baseline VOSL, representing the
average value for people of average age (40
years) and average health in various contexts.
Adjustments were made to this baseline value
to allow for the older age and impaired health
of those affected by air pollution: WTP
among those > 65 years old was stated to be
approximately 70% of WTP among those of
40 years old, whereas adjustment for life
expectancy ranged from no adjustment (aver-
age 12 years at age 65) to 1 year to 1 month.
Therefore WTP would be reduced by zero,
one-twelfth, or one-twelfth of one-twelfth
respectively. Those affected also often have a
lower quality of life than average [0.76 using
the EuroQual quality of life questionnaire
instrument (EAHEAP 1999)] for their age of
between 0.2 and 0.7. Given that a lower qual-
ity of life may be expected to reduce WTP,
we assumed WTP to decrease in proportion
to quality of life, by a factor of 0.2/0.76 to
0.7/0.76. This produces a range of VOSL
from £1.4 million to a WTP of £2,600. The
age-adjusted-only value was used in this
study, while the lower bound was used in a
sensitivity analysis.
Costs for catalysts were based on the rec-
ommended retail price for a replacement cat-
alyst because no ofﬁcially published ﬁgure for
the cost of VECs exists for Europe (DETR
1998a). Various motor manufacturers and
organizations were approached but none
agreed to disclose any data, citing restrictions
placed by commercial confidentiality. The
value used in this work was, therefore, a
weighted average retail price for the replace-
ment cost of a catalyst (excluding value-
added tax), where the weighting took into
consideration the makes and models of the
most popular automobiles registered in the
United Kingdom in 1994 (the closest year to
1992 for which data were available). A
weighted average of £227.29 in 1998 prices
was thus derived.
The capital costs of catalysts were “annu-
alized” through the use of annuity rates given
by the formula A(n,r) = r/(1 – (1 + r)–n),
where A = annuity, r = discount rate, and n =
lifetime of converter (13 years). This enabled
the study to ascribe an annual VEC charge for
each relevant year of use, and so allows for the
capital costs (principal plus interest) relating to
catalysts still in use beyond the period of the
study. Discounting is the process whereby
the values of future effects are adjusted to
make them comparable to the values placed
on current consumption, costs, and beneﬁts,
because a given amount of future consump-
tion is worth less than the same amount of
consumption today. Present values are
obtained by multiplying the future values of
a policy’s effects by discount factors that
reﬂect both the amount of time between the
present and the point at which these events
occur and the degree to which current con-
sumption is more highly valued than future
consumption. A U.K. public sector discount
rate of 6% was used in this work. For dis-
counting the net benefits, we used a U.K.
public sector discount rate of 6%. The mone-
tary values used for the central estimate in this
study, normalized to 1998 Great Britain
pounds, are shown in Table 1. A 1998 $US
equivalent may be derived using a purchasing
power parity adjusted exchange rate of 0.66
(i.e., £1998 divided by 0.66)
Environmental Surveys
Although no currently known health effects
are associated with the platinum forms emit-
ted from VECs (metal and oxide), adverse
health effects have been observed in occupa-
tional studies of exposure to various platinum
compounds, particularly halogenated plat-
inum salts (HSE 1990; Merget 2000; Rosner
and Merget 1990). Because the possibility
remains of future transformation in the envi-
ronment of platinum and platinum oxides,
we investigated whether any changes had
occurred in the levels of platinum and lead in
soils and road dusts in the U.K. urban envi-
ronment since the 1993 introduction of
VECs as part of this study. To do this, envi-
ronmental surveys were conducted in the
cities of Nottingham and Birmingham.
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Table 2. Estimated physical and health effects and economic valuations from reductions in U.K. urban pollution from VECs, 1993–1998 (actual) and 1993–2005 (projected).
PM10
a PM10
a O3
b O3
b NO2 NO2
Effects 1993–1998 1993–2005 1993–1998 1993–2005 1993–1998 1993–2005
Physical effects (reductions in concentrations)
Average ambient urban concentration in 1992 26.6 (µg/m3) 15.28 (ppb) 29.58 (ppb)
Estimated reduction in pollutant (unit) 0.92 (µg/m3) 2.24 (µg/m3) –0.46 (ppb) –1.04 (ppb) 2.45 (ppb) 5.59 (ppb)
Health effects (mortality and morbidity)
e-r function mortalityc 0.074 0.074 0.106 0.106
(0.044–0.075)d (0.044–0.075)d (0.051–0.153)e (0.051–0.153)e
Reduction in deaths brought forwardf 1,186 5,859 –391 –1,832
(705–1,202) (3,483–5,938) (–188 to –565) (–878 to –2,634)
e-r function morbidityg 0.08 0.08 0.137 0.137 0.096 0.096
(0.045–0.11)d (0.045–0.11)d (0.061–0.210)e (0.061–0.210)e (0.008–0.187)e (0.008–0.187)e
Reduction in respiratory hospital admissions 1,454 7,185 –345 –1,609 2,833 13,050
(818–2,000) (4,042–9,879) (–153 to –528) (–713 to –2,459) (227–5,553) (1,044–25,578)
Economic evaluation of present values of net beneﬁts (£1998)
Present value of total beneﬁts £millionh 1953.86 7,378 –644.49 –2,306.30 8.39 29.72
(1160.74–1983.58) (4,383–7,490) (–310.10–931.48) (–1109.71 to –3333.29) (0.43–21.32) (1.51–75.54)
Present value of costs of VECs £million 808.15 2944.5
Total beneﬁts net of catalyst costs £millioni 509.61 2156.9
Results in Table 2 represent estimates of selected health beneﬁts based on applying central, lower, and upper bound estimates for exposure response (e-r) functions to the inferred
reduction in urban pollution arising from the use of vehicle exhaust catalysts. Where a range of exposure response functions was unavailable, the upper and lower 95% conﬁdence
intervals for the available function were used to present a lower and upper bound range. 
aPrimary and secondary. bSummer. cPercent change in mortality rate per unit pollutant; selected e-r functions were all adjusted for co-exposure to other pollutants. dLower and upper
bounds selected from other studies. e95% CI when only one study available, except for NO2 where two studies were combined and represents lowest and highest CI from the individual
studies used. fAll causes. gPercent change in morbidity rate per unit pollutant; selected e-r functions were all adjusted for co-exposure to other pollutants. hFigures in parentheses rep-
resent low and high economic valuation estimates for morbidity respectively (comprising WTP to avoid hospital admission and NHS hospital costs). iCentral estimate.Detailed methods and results have been pub-
lished elsewhere (Farago et al. 1996; Hall and
Pelchat 1994; Hutchinson et al. 2000).
Platinum was not, however, included in the
health risk assessment model in this evalua-
tion because of the absence of any clearly
established health effect.
Results
Estimated reductions in urban concentrations
of PM10, O3, NO2, CO, and VOCs (relative
to 1992 levels) associated with the use of
VECs are illustrated in Figure 2. Table 2
shows the results of the health impacts valua-
tion model, both for 1993–1998 and for the
projections to 2005. The health effects
avoided by the reduction in PM10 dominate
these valuation estimates, because of both the
estimated large decrease in the number of
deaths brought forward and the higher eco-
nomic values used for reductions in mortality
risk relative to morbidity risk. This large
decrease in the number of deaths brought for-
ward results from the relatively high expo-
sure–response function associated with PM10
and the comparatively high estimated reduc-
tion in ambient concentration associated with
the use of VECs. In line with current proto-
col, we assumed the health effects of each pol-
lutant to be additive and summed the values
to produce an overall result. For urban Great
Britain, on the health beneﬁts quantiﬁed, net
beneﬁts of £510 million to 1998 and £2,157
million to 2005 were estimated.
Because nitric oxide is a scavenger of
ozone, reductions in urban emissions of NOx
lead to increases in estimated urban ground
level ozone concentrations (DETR 1998a).
Derwent (1999) has suggested that as NOx
emissions from motor vehicles approach zero,
urban NOx levels would decrease and urban
ozone levels would eventually rise to the levels
in the rural areas surrounding them. We
quantified health effects for the summer
period only (April–September) because the
exposure–response relationships show a
stronger association between ozone and
health effects for the summer months, when
ozone concentrations are higher. Results of
the present model (Table 2) show a consider-
able negative impact of NOx reduction on
ozone-related health effects, with an estimated
391 deaths brought forward and 345 addi-
tional or brought-forward hospital admissions
by 1998, and an estimated 1,832 and 1,609
respectively by 2005; however, reductions in
urban precursor emissions for ozone can be
expected to contribute to reductions in rural
ozone levels. The decreases in PM10 and
NO2, on the other hand, suggest significant
reductions in these health end points. The
greatest beneﬁt in terms of morbidity appears
to be associated with NO2 reductions [in line
with results from the economic analysis of the
National Air Quality Strategy Objectives
(DETR 1998a)].
Recent published estimates for the VOSL
have been considerably higher than the cen-
tral value used here; this has been historically
the case for estimates derived in U.S. studies
[£2.66 million (Desvousges et al. 1998);
£1.99 million (Levy et al. 2001)], and has also
been reflected in a recent European meta-
analysis [£3.87 million (EC 2000)]. Estimates
based on the latter two values provide a fur-
ther sensitivity analysis, producing estimated
net beneﬁts three to ﬁve times larger than the
figures in Table 2: They range from £1,533
million to £2,588 million by 1998, and from
£6,108 million to £10,207 million by 2005,
respectively. This is illustrated in Figures 3
and 4.
Because individuals with pre-existing dis-
ease are more susceptible to adverse effects
from air pollution, and deaths are not solely
additional but consist of deaths brought for-
ward and additional deaths, valuing years of
life lost would be preferable to estimating the
VOSL per se. No robust estimates of the
extent to which deaths are brought forward
are currently available which can reasonably
be applied to time-series studies (COMEAP
2001), although the U.K. Department for
Environment, Food and Rural Affairs has
commissioned studies to investigate and value
reductions in the quality and length of life—
focusing specifically on risks from air pollu-
tants (Maynard R. Personal communication).
If these estimates were signiﬁcantly less than
the VOSL estimates, they would reduce the
estimated net benefits below those shown in
Table 2: Sensitivity analysis shows that the
value of VOSL would have to fall below £1
million to result in a negative beneﬁt.
A ﬁrst approximation of the value of years
of life lost, of £0.0028 million, is provided by
EAHEAP (1999). This value is not, however,
a true VOSL value but rather an adjusted esti-
mate of VOSL allowing for an estimated min-
imum reduction in life expectancy (based on
current value judgments) and possible maxi-
mum reduction in the quality of life because
of the health effects of air pollutants. It is
therefore not directly comparable with the
other VOSL values used in this work; rather,
it represents a possible minimum value for life
years lost, and is used here only as an addi-
tional sensitivity analysis to represent the
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Figure 3. Benefits, costs, and net benefits for selected scenarios to 1998. For the results presented in
Figures 3 and 4, VOSL estimates were taken from EAHEAP (1999; base estimate), Desvousges et al. (1998;
higher VOSL A), and Day (2000; higher VOSL B). In all other respects, the same parameters were used for
the three estimates presented above.
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Figure 4. Benefits, costs, and net benefits for selected scenarios to 2005. For the results presented in
Figures 3 and 4, VOSL estimates were taken from EAHEAP (1999; base estimate), Desvousges et al. (1998;
higher VOSL A), and Day (2000; higher VOSL B). In all other respects, the same parameters were used for
the three estimates presented above.
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Estimated net benefits based on this value
were –£794.1 million to 1998 and –£2892.8
million to 2005.
Environmental Survey
The results of the environmental survey
showed signiﬁcant increases in concentrations
of platinum in both soils and dusts since the
early 1980s. Measurement of metal concentra-
tions in road dust represents recent deposition
from traffic sources, as road dust is washed
away periodically by rain water. Platinum lev-
els in Nottingham road dust in 1998 were cor-
related with traffic density: e.g., a geometric
mean value of 160.3 ng/g Pt was observed in
city center road dust, compared to 30 ng/g in
that from residential roads, whereas overall
levels in the city increased from 0.8 ng/g Pt in
1982 to 70 ng/g in 1998. An estimate of the
increase in total platinum emissions in the
United Kingdom was also made through the
use of traffic data (DETR 1999; Simoni S.
Personal communication) and emissions fac-
tors produced from test bench studies (Artelt
et al. 1999). Total urban platinum emissions
from catalysts for the United Kingdom were
projected to be in the range of 13–45 kg to
1998, and 59–210 kg to 2005.
A large (50%) reduction in lead concentra-
tions in road dust was found (from 1,100 µg/g
in 1982 to 500 µg/g in 1998), but no statisti-
cally signiﬁcant reduction in soil [195 µg/g in
1982 and 236 µg/g in 1998, respectively;
Hutchinson (2001)].
Discussion
The cost–benefit analysis presented above
suggests that by 1998, on the beneﬁts quanti-
fied, a positive net health benefit had been
reached from the use of VECs, and much
larger net benefits are anticipated with full
catalyst penetration by 2005. The projected
estimates for health beneﬁts and their valua-
tion to 2005 were based on relatively simple
modeling, and assumptions had to be made
to produce these estimates within the scope of
this study (e.g., although we allowed for the
projected increase in traffic growth, we
assumed that all nontrafﬁc emissions remained
constant, and no evidence was available on the
performance of VECs with increasing
mileage). However, with these caveats, by
2005 a further positive net benefit seems
likely to be achieved with regard to reductions
in deaths brought forward and reductions in
additional or brought-forward respiratory
hospital admissions.
The general approach in this study was to
err on the side of caution, with the aim of
reducing the risks of overestimating net health
beneﬁts. Consequently, estimates were excluded
where there was signiﬁcant uncertainty about
relationships and/or parameters or other data.
Had other associated health effects been
included, such as those for symptoms and
chronic effects and for the omitted but poten-
tially damaging pollutants [VOCs, polycyclic
aromatic hydrocarbons (PAHs), lead], a further
increase in health beneﬁts would be expected.
The particular exception was the effect on rural
ozone of reducing urban precursor emissions.
Any effects arising from changes in global or
regional pollutants (except low-level ozone)
also lay beyond the scope of this study,
although they merit examination [for example,
catalysts increase nitrous oxide emissions
(Wade et al. 1994)]. Other factors, such as the
possible health disbeneﬁts from increased plat-
inum exposure and the environmental impacts
of increasing platinum production, were
excluded because of insufficient evidence
through which to quantify them. In our view,
however, although there is no current evidence
of adverse health effects arising from VEC plat-
inum emissions, the rapid increase in platinum
deposition warrants continued monitoring, as
adverse health effects have been observed in
occupational studies of exposure to various
platinum compounds. The environmental sur-
vey results highlight the potential complexities
of bringing in technologic solutions to pollu-
tion control—in this case although several pol-
lutant emissions have decreased (e.g., CO,
NOx, PM10, VOCs, lead), other pollutants,
such as platinum, whose effects are not yet
fully understood, have increased.
Because our current work is primarily a
health risk assessment, we have constrained our
analyses to the effects of local urban air pollu-
tion. The effects on rural ozone of reducing
urban precursor emissions are complex and lie
beyond the primarily urban focus of this work.
Furthermore, with only 15% of the Great
Britain population living in rural areas, we
judged that any positive health effects arising
from reducing urban precursor emissions
would be unlikely to have a relatively large
health impact on the overall population
(although such effects would undeniably affect
rural dwellers and other receptors, such as
plants). Nevertheless, recent research gives
some impression of current trends in rural
ozone: A downward trend has been observed in
annual maxima from national U.K. monitor-
ing site data since the 1980s, although this was
not signiﬁcant for most sites [National Expert
Group on Transboundary Air Pollution
(NEGTAP) 2001], whereas in an analysis of
ﬁve rural sites over 1984–1998 (of meteorolog-
ically adjusted summer daily maxima),
Gardner and Dorling (2000) found a down-
ward trend of –0.7 to –2.3 ppb/year.
On the cost side, the catalyst costs used
here are likely to overestimate those borne by
car manufacturers: In the absence of quoted
manufacturers’ data, they were based on retail
prices for replacement catalysts (excluding
value-added tax). Data on catalyst recycling
were also not available. There is, however, the
possibility that catalysts would have to be
replaced during the time span considered
(thus increasing costs) or might deteriorate
over time (thus decreasing beneﬁts). However,
catalysts are designed to be operational for the
automobile’s lifetime and should not require
replacement if they are appropriately main-
tained (Department of Transport 1995). The
California Air Resources Board estimated a
sales weighted average worldwide cost to man-
ufacturers for “tailpipe emission control” of
US$324 in 1990 (Wang et al. 1993). Using
purchasing power parity adjusted exchange
rates and allowing for inﬂation, this is equiva-
lent to £250 in 1998 prices. This is 10% more
than the £227 used in this study, although
advances in VEC production and volume
since 1990 might have reduced U.S. costs.
Since this work was carried out, a new
U.K. public sector discount rate of 3.5% was
recommended in February 2003 (Her
Majesty’s Treasury 2003). This ﬁgure, closer
to the rate often used in U.S. health evalua-
tion studies [e.g., Grosse et al. (2002) used
3%, with sensitivities of 0 and 5%], would
have the effect of increasing the estimated net
benefits. A previously conducted sensitivity
analysis for this work using discount rates of 3
and 0%, respectively, produced estimated net
beneﬁts of £615 million and £698 million to
1998 and projected net benefits of £2,886
million and £3,705 million to 2005 respec-
tively. Use of the 6% discount rate in this
article is consistent, therefore, with a relatively
cautious approach to evaluation.
Carbon Monoxide, VOCs, and PAHs
We judged it not possible reliably to estimate
the health impacts arising from the catalyst-
induced reductions in emissions of Pb, VOCs,
and PAHs at this time, although it seems
likely that these reductions would yield further
positive health beneﬁts.
Although beneﬁts were initially quantiﬁed
for CO, the net beneﬁt values presented here
also omit the results for CO, because of
uncertainty about how the exposure–response
relationships derived from epidemiologic
time-series studies conducted in the United
States and in Athens, Greece, relate to the low
concentrations of carbon monoxide found in
the United Kingdom (Schwartz 1999;
Touloumi et al. 1996). More research is
needed in this area to determine whether and
to what extent health effects associated with
CO are likely at these low exposures. It has
been suggested that exposure functions for
CO may represent a proxy for the health
effects of other pollutants associated with traf-
fic pollution; potential pollutants that have
been suggested as also possibly having acute
cardiovascular toxicity are the VOCs
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untested at present. Additionally, current
thinking attributes some cardiovascular toxic-
ity to particulate matter (Medina et al. 2002).
In a program funded by the European
Union, intended to evaluate the externalities
associated with transport in Europe (EC
1999), effects on health were estimated as
well as other external costs, such as accidents.
Case studies quantifying damage estimates for
health, crops, and buildings were conducted
for countries including the United Kingdom.
Health impacts dominated the damages
quantiﬁed, particularly those associated with
mortality from primary and secondary PM10.
Long-term health effects associated with car-
cinogens (such as PAHs and benzene) were also
quantiﬁed but were of much lower importance
than particles because the former are emitted
only in small quantities. This suggests that, in
this work, inclusion of chronic carcinogenic
effects for PAHs would have been unlikely to
alter the health beneﬁts substantially.
The quantiﬁcation of the potential health
effects from reductions in lead emissions in this
study was problematic for several reasons,
First—and decisively—difﬁculties were experi-
enced in identifying the role of catalysts in
reducing lead emissions, caused by lack of
appropriate data on the relationships between
unleaded fuel consumption in the United
Kingdom and the factors (in addition to VEC
introduction) that have influenced them,
including decreased permitted levels of lead in
petrol in 1981 and 1985 and the tax-related
price differential between leaded and unleaded
petrol introduced in 1989 (DETR 1998b).
Second, although exposure–response functions
for end points other than those used in this
work are available for lead (specifically for
blood lead and IQ), there is some controversy
over the causal nature of the IQ association:
Although many studies support such an associ-
ation, they have been criticized because of their
inability to account for all confounding factors;
hence, it remains possible that the relationship
is not causal (Expert Panel on Air Quality
Standards 1998). For instance, children of a
lower average intelligence may be more likely
to be exposed to lead as a result of their habits
and the quality of housing in which they live.
Nevertheless, recent studies with better control
for social confounding have given more sup-
port to the relationship between blood lead
and IQ particularly in the United States
(DETR 1997; Grosse et al. 2002). Third,
uncertainty has also been expressed about the
relationship between changes in blood lead and
health effects at normal levels (Institute for
Environment and Health 1998).
Exposure–Response Functions
Since this research was carried out, further expo-
sure–response functions have been estimated by
Air Pollution and Health: A European
Information System (APHEIS) in their sec-
ond-year report on the health impact assess-
ment of air pollution in 26 cities (Medina et
al. 2002). For a 10-µg/m3 increase in PM10,
the following changes were estimated: 1.006
[95% conﬁdence interval (CI), 1.004–1.008]
change in mortality rate (all ages); 1.009 (95%
CI, 1.006–1.013) change in respiratory hospi-
tal admissions rate in ≥ 65 age group; and
1.005 (95% CI, 1.002–1.008) in cardiac hos-
pital admissions rate for all ages (ICD9 codes
410–414, 427, 428). Using these functions in
this work would have the effect of slightly low-
ering the decrease in the estimated numbers of
deaths brought forward, but slightly raising
the decrease in respiratory hospital admissions.
Cardiac admissions were not considered in the
current evaluation, because of uncertainty and
lack of existing agreement regarding this end
point for PM10. Inclusion of this end point
would, of course, result in a further estimated
decrease in hospital admissions and a conse-
quent increase in estimated beneﬁts. In addi-
tion to this, in the studies used for the
selection of exposure–response functions in
this work, lag times of 0–1 day were generally
assumed. However, there is currently a move
toward looking at longer lag times (≤ 40 days)
to investigate further whether associated
deaths are solely brought forward (and so a
decrease in deaths would be expected a few
days later) or might be additional. In a meta-
analysis of daily deaths associated with PM10
in 10 of the APHEA cities, Zanobetti et al.
(2002) report an exposure–response function
of 1.61% (95% CI, 1.02–2.20) increase in
daily deaths (all cause mortality) using a 40-
day lag. Substitution of this function in this
work would produce a larger estimated
decrease in deaths from PM10 and a conse-
quent increase in estimated benefits.
Nevertheless, exposures on the day of death
and the immediately preceding day still had
the greatest impact on mortality in the
Zanobetti study (2002).
Recently, Levy et al. (2001) reviewed
exposure–response functions for ozone from
studies conducted in the United States and
produced a central estimate, using meta-
analysis, relative to the United States of 0.5%
(95% CI, 0.3–0.7%) increase in premature
deaths per 10-µg/m3 increase in 24-hr average
ozone concentrations. Inclusion of two
European studies produced a pooled estimate
of 0.6% (95% CI, 0.4–0.9%). This estimate
is compatible with that used in this study
(0.05%/1 µg/m3 O3)—although the latter is
based on an 8-hr average concentration.
We acknowledge that our use of time-
series studies precluded consideration of
long-term health effects. Had we felt it
appropriate to use exposure–response func-
tions from cohort studies, our estimates of
benefits probably would have risen. The
exposure–response functions used in this
work represent a cautious estimation of
health effects, and it is likely that in future
epidemiologic studies, health effects, includ-
ing symptoms, of a greater magnitude may
be associated with urban air pollution.
Future research may also enable more precise
identiﬁcation and estimation of effects associ-
ated with particular size fractions of particu-
late matter.
Estimates from Related Studies
Few U.K. studies of the effects of air pollu-
tion on health have attempted to quantify
health beneﬁts from reductions in emissions.
Most, such as the COMEAP (1998) and
EAHEAP (1999) studies, present estimates of
health effects associated with concurrent
ambient pollution levels or per unit of pollu-
tion. However, the economic analysis of the
National Air Quality Strategy objectives
(DETR 1998a) estimates beneﬁts for various
emissions reduction scenarios with respect to
London. Three scenarios were examined,
including a “business as usual” scenario repre-
senting the expected effect of current policies.
In this scenario, numbers for reductions in
deaths brought forward and reductions in res-
piratory hospital admissions (additional or
brought forward) expected to result from the
reduction in pollution levels from current poli-
cies by the years 2000, 2004, and 2005, rela-
tive to a baseline of 1995, were projected:
From 1995 to 2005, 5,120 fewer deaths
brought forward were estimated to follow
from PM10 reductions, whereas total reduc-
tions in emergency respiratory hospital admis-
sions were estimated to be 4,225 for PM10
and 8,255 for NO2 reductions. Because these
estimates represent pollution reductions from
all current environmental policies, they would
be expected to produce higher estimates of
beneﬁts than those in this article for the effects
of reduced pollution from vehicle exhaust cat-
alyst use alone. Whereas this is so for PM10
(primary PM10 only), for NO2 the estimates
in this article are higher. Because the quantiﬁ-
cation of health beneﬁts in this article is based
on the same exposure–response function, it is
possible that the difference arises either from
lower estimates of emissions reductions or
from the estimation of the relationship
between the reduction in emissions of NOx
and the corresponding reduction in NO2 con-
centrations. In relation to the latter, in the
economic analysis of the NAQS report, rela-
tively sophisticated mapping techniques devel-
oped by NETCEN were employed, whereas
in the current work we used a simpler rela-
tionship produced by the South East Institute
of Public Health (Carslaw et al. 1998). Such
techniques lay outside the scope and resources
of the research reported here.
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Evaluations
Although the estimates in Table 2 suggest
that the introduction of this pollution abate-
ment technology has produced substantial
actual and projected positive net benefits—
and this is a useful ﬁnding—these results do
not establish that the mandating of VECs was
necessarily the best policy option; alternative
policies or actions might conceivably have led
to larger beneﬁts or a reduction in cost. This
emphasizes the value of undertaking ex ante
evaluations of sets of alternative environmen-
tal policy interventions, to assist in the devel-
opment of effective, appropriate pollution
control policy strategies, as well as ex post
appraisals of the net beneﬁts realized from the
chosen instrument(s).
Conclusion
In an era when growing concern over the
health effects of pollution has led govern-
ments to adopt increasingly stringent emis-
sion controls, this study shows how relatively
straightforward techniques can be used to
evaluate policy measures. The study represents
the ﬁrst major attempt to quantify and value
net health beneﬁts from the mandated intro-
duction of VECs, both for the United
Kingdom and elsewhere. For the pollutants
and health effects quantiﬁed, the results sug-
gest that between 1993 and 1998 there were
substantial health beneﬁts in excess of the costs
of VECs. Projections through 2005, when full
catalyst penetration is expected, suggest net
beneﬁts of more than £2 billion. An increase
in platinum levels of up to 90 times the natu-
ral background was observed only 5 years after
the introduction of VECs. Although no nega-
tive health effects from platinum emissions
have yet been identiﬁed, in view of the appar-
ent rapid accumulation rate of platinum into
the environment, the situation warrants con-
tinued monitoring.
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